Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== External links == Goudarzi, Sara (9 June 2006). "Yogurt Culture Evolves". LiveScience. Archived from the original on August 29, 2008. Retrieved 2013-01-14. Type strain of Lactobacillus delbrueckii subsp. bulgaricus at BacDive - the Bacterial Diversity Metadatabase "Lactobacillus delbrueckii". microbewiki.kenyon.edu – Microbe Wiki. Retrieved 2019-11-14.
Chlorarachniophytes, which belong to the phylum Cercozoa, contain a small nucleomorph, which is a relict of the algae's nucleus. Euglenophytes, which belong to the phylum Euglenozoa, live primarily in fresh water and have chloroplasts with only three membranes. The endosymbiotic green algae may have been acquired through myzocytosis rather than phagocytosis. Another group with green algae endosymbionts is the dinoflagellate genus Lepidodinium, which has replaced its original endosymbiont of red algal origin with one of green algal origin. A nucleomorph is present, and the host genome still have several red algal genes acquired through endosymbiotic gene transfer. Also, the euglenid and chlorarachniophyte genome contain genes of apparent red algal ancestry. Other groups have "red" chloroplasts containing chlorophylls a and c, and phycobilins. The shape can vary; they may be of discoid, plate-like, reticulate, cup-shaped, spiral, or ribbon shaped. They have one or more pyrenoids to preserve protein and starch. The latter chlorophyll type is not known from any prokaryotes or primary chloroplasts, but genetic similarities with red algae suggest a relationship there. In some of these groups, the chloroplast has four membranes, retaining a nucleomorph in cryptomonads, and they likely share a common pigmented ancestor, although other evidence casts doubt on whether the heterokonts, Haptophyta, and cryptomonads are in fact more closely related to each other than to other groups.
If a pregnant woman has serum hCG levels that are higher than expected, they may be experiencing a multiple pregnancy or an abnormal uterine growth. Falling hCG levels may indicate the possibility of a miscarriage. hCG levels which are rising at a slower rate than expected may indicate an ectopic pregnancy.
=== Disease === One of the major causes of amputation in medieval Europe was disease. Ergotism (also known as Saint-Anthony's fire) was a fungus found in rye that caused gangrene that spread from the fingers and toes. If the tissue death from the disease was severe enough, the limb would spontaneously fall off on its own without blood loss.
Sources: en.wikipedia.org
On 31 August 1980, representatives of workers at the Gdańsk Shipyard, led by an electrician and activist Lech Wałęsa, signed the Gdańsk Agreement with the government that ended their strike. Similar agreements were concluded in Szczecin (the Szczecin Agreement) and in Silesia. The key provision of these agreements was the guarantee of the workers' right to form independent trade unions and the right to strike. Following the successful resolution of the largest labor confrontation in communist Poland's history, nationwide union organizing movements swept the country. Edward Gierek was blamed by the Soviets for not following their "fraternal" advice, not shoring up the communist party and the official trade unions and allowing "anti-socialist" forces to emerge. On 5 September 1980, Gierek was replaced by Stanisław Kania as first secretary of the PZPR. Delegates of the emergent worker committees from all over Poland gathered in Gdańsk on 17 September and decided to form a single national union organization named "Solidarity". While party–controlled courts took up the contentious issues of Solidarity's legal registration as a trade union (finalized by November 10), planning had already begun for the imposition of martial law. A parallel farmers' union was organized and strongly opposed by the regime, but Rural Solidarity was eventually registered (12 May 1981). In the meantime, a rapid deterioration of the authority of the communist party, disintegration of state power and escalation of demands and threats by the various Solidarity–affiliated groups were occurring.
The jalapeño ( HA(H)L-ə-PEE-nyoh, -PAY-, Spanish: [xalaˈpeɲo] ) is a medium-sized chili pepper pod type cultivar of the species Capsicum annuum. A mature jalapeño chili is 5–10 cm (2–4 in) long and 25–38 mm (1–1+1⁄2 in) wide, and hangs down from the plant. The pungency of jalapeño peppers varies, but is usually between 4,000 and 8,500 units on the Scoville scale. Commonly picked and consumed while still green, it is occasionally allowed to fully ripen and turn red, orange, or yellow. It is wider and generally milder than the similar Serrano pepper.
==== Local application to the breasts ==== Transdermal application of progesterone with the intention of systemic therapy should not be equated with local treatment. The site of application of transdermal progesterone has been found to significantly influence its absorption. When transdermal progesterone is applied to the breasts, high concentrations within breast tissue have been observed. In one study, a 3- to 5-fold increase in local progesterone levels in the breast was observed with 50 mg transdermal progesterone in an alcohol/water-based gel applied to each breast in premenopausal women. In another study, a 70- to 110-fold increase in local concentrations of progesterone in the breasts was measured with application of a hydroalcoholic gel to the breasts in premenopausal women. A study observed a significant increase in circulating levels of progesterone when it was applied as a topical ointment to the breasts but not when it was applied to other areas like the thigh or abdomen. However, two other studies observed no apparent increase in circulating levels of progesterone with transdermal application of progesterone to the breasts. On the basis of its 10% transdermal bioavailability when applied to the breasts, a 50 mg dose of progesterone applied transdermally may result in a local concentration of progesterone in the breasts equivalent to 5 mg.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.